07:00 , Aug 18, 2014 |  BC Week In Review  |  Clinical News

Corifollitropin alfa regulatory update

Merck disclosed in its 2Q14 financial results that FDA issued a complete response letter for corifollitropin alfa for controlled ovarian stimulation to treat infertility in women participating in assisted reproductive technology (ART). The pharma declined...
01:12 , Jul 30, 2014 |  BC Extra  |  Financial News

Merck CEO not interested in inversion deals

Merck & Co. Inc. (NYSE:MRK) is not interested in pursuing deals "solely or primarily for the specific purpose of tax inversion," said CEO and Chairman Kenneth Frazier during a conference call to discuss the pharma's...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Clinical News

Corifollitropin alfa regulatory update

FDA accepted for review an NDA from Merck for corifollitropin alfa for controlled ovarian stimulation to treat infertility in women participating in assisted reproductive technology (ART). The PDUFA date is not disclosed. Merck said the...
08:00 , Feb 1, 2010 |  BC Week In Review  |  Clinical News

Elonva corifollitropin alfa regulatory update

The EC approved an MAA from Merck for Elonva corifollitropin alfa injection for controlled ovarian stimulation in combination with a gonadotrophin-releasing hormone (GnRH) antagonist for the development of multiple follicles to treat infertility in women...
08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

Elonva corifollitropin alfa regulatory update

EMEA's CHMP issued a positive opinion on an MAA from Merck for Elonva corifollitropin alfa for use in controlled ovarian stimulation in combination with a gonadotropin-releasing hormone (GnRH) antagonist to treat infertility. The application for...
07:00 , Jul 6, 2009 |  BC Week In Review  |  Clinical News

Corifollitropin alfa: Phase II data

Data from 50 women undergoing ovarian stimulation in the open-label, uncontrolled Phase II REALIZE trial showed that 100 and 150 ug corifollitropin alfa followed by Follistim follitropin beta recruited 17.5 +/-5.5 and 18.3 +/-6.4 follicles...
07:00 , Jul 6, 2009 |  BC Week In Review  |  Clinical News

Corifollitropin alfa: Phase III data

Data from the double-blind, international Phase III ENSURE trial showed that 100 ug corifollitropin alfa significantly increased the number of oocytes retrieved in 396 women weighing <=60 kg and undergoing ovarian stimulation vs. 150 ug...
07:00 , Mar 16, 2009 |  BioCentury  |  Strategy

Merck/Schering-Plough pipeline

Merck/Schering-Plough pipeline By acquiring Schering-Plough (NYSE:SGP), Merck (NYSE:MRK) will nearly double the number of Phase III compounds it has in development. The analysis below, which focuses on compounds and vaccines in Phase II, Phase III...
07:00 , Mar 16, 2009 |  BioCentury  |  Strategy

Merck's challenges

The merger of Merck & Co. Inc. and Schering-Plough Corp. combines complementary pipelines that could make shareholders happy in the short term by maintaining Merck's dividend and delaying the loss of revenues from patent expirations....
08:00 , Jan 5, 2009 |  BC Week In Review  |  Clinical News

Corifollitropin alfa regulatory update

EMEA accepted for review an MAA from Schering-Plough for subcutaneous Corifollitropin alfa to treat infertility. The application was made under the centralized procedure. The company said the follicle stimulating hormone (FSH) is being developed for...